Q3 Earnings Forecast for Savara Issued By Lifesci Capital

Savara Inc. (NASDAQ:SVRA) – Investment analysts at Lifesci Capital issued their Q3 2025 earnings per share (EPS) estimates for shares of Savara in a report released on Tuesday, October 14th. Lifesci Capital analyst F. Brisebois forecasts that the company will earn ($0.14) per share for the quarter. Lifesci Capital has a “Strong-Buy” rating on the stock. The consensus estimate for Savara’s current full-year earnings is ($0.45) per share. Lifesci Capital also issued estimates for Savara’s Q4 2025 earnings at ($0.15) EPS, FY2025 earnings at ($0.55) EPS, Q1 2026 earnings at ($0.13) EPS, Q2 2026 earnings at ($0.13) EPS, Q3 2026 earnings at ($0.14) EPS, Q4 2026 earnings at ($0.11) EPS and FY2026 earnings at ($0.51) EPS.

Several other analysts also recently commented on SVRA. Oppenheimer upped their price objective on Savara from $6.00 to $8.00 and gave the company an “outperform” rating in a research note on Monday, September 8th. HC Wainwright boosted their target price on Savara from $5.00 to $8.00 and gave the stock a “buy” rating in a research report on Wednesday, September 3rd. Weiss Ratings reiterated a “sell (d-)” rating on shares of Savara in a research report on Wednesday, October 8th. Finally, Guggenheim boosted their target price on Savara from $8.00 to $11.00 and gave the stock a “buy” rating in a research report on Tuesday, September 9th. One research analyst has rated the stock with a Strong Buy rating, five have given a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $7.50.

Savara Stock Down 0.6%

SVRA opened at $3.58 on Thursday. The business has a 50 day moving average price of $3.37 and a two-hundred day moving average price of $2.88. The company has a quick ratio of 11.08, a current ratio of 11.08 and a debt-to-equity ratio of 0.25. The company has a market cap of $618.77 million, a PE ratio of -7.16 and a beta of 0.46. Savara has a 52 week low of $1.89 and a 52 week high of $4.30.

Savara (NASDAQ:SVRA) last posted its quarterly earnings data on Wednesday, August 13th. The company reported ($0.14) EPS for the quarter, missing the consensus estimate of ($0.12) by ($0.02).

Institutional Investors Weigh In On Savara

Large investors have recently bought and sold shares of the stock. Rhumbline Advisers lifted its stake in shares of Savara by 8.6% during the 1st quarter. Rhumbline Advisers now owns 153,542 shares of the company’s stock worth $425,000 after purchasing an additional 12,117 shares during the period. Farther Finance Advisors LLC raised its position in shares of Savara by 25.3% in the 1st quarter. Farther Finance Advisors LLC now owns 32,314 shares of the company’s stock worth $92,000 after buying an additional 6,532 shares during the period. Bank of New York Mellon Corp raised its position in shares of Savara by 3.7% in the 1st quarter. Bank of New York Mellon Corp now owns 262,935 shares of the company’s stock worth $728,000 after buying an additional 9,305 shares during the period. Emerald Mutual Fund Advisers Trust increased its holdings in Savara by 46.4% in the 1st quarter. Emerald Mutual Fund Advisers Trust now owns 2,014,456 shares of the company’s stock valued at $5,580,000 after purchasing an additional 638,568 shares in the last quarter. Finally, Emerald Advisers LLC increased its holdings in Savara by 32.5% in the 1st quarter. Emerald Advisers LLC now owns 3,090,213 shares of the company’s stock valued at $8,560,000 after purchasing an additional 757,533 shares in the last quarter. Institutional investors and hedge funds own 87.93% of the company’s stock.

Savara Company Profile

Savara Inc, formerly Mast Therapeutics, Inc, is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Its pipeline includes AeroVanc, Molgradex and AIR001. AeroVanc is an inhaled formulation of vancomycin, which the Company is developing for the treatment of persistent methicillin-resistant Staphylococcus aureus, lung infection in cystic fibrosis patients.